Cargando…
Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466856/ https://www.ncbi.nlm.nih.gov/pubmed/32934883 http://dx.doi.org/10.1080/2162402X.2020.1779991 |
_version_ | 1783577904209199104 |
---|---|
author | Naseri, Marzieh Bozorgmehr, Mahmood Zöller, Margot Ranaei Pirmardan, Ehsan Madjd, Zahra |
author_facet | Naseri, Marzieh Bozorgmehr, Mahmood Zöller, Margot Ranaei Pirmardan, Ehsan Madjd, Zahra |
author_sort | Naseri, Marzieh |
collection | PubMed |
description | Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived exosomes (TEXs) are nanosized lipid bilayer encapsulated vesicles that shuttle bioactive information to the tumor microenvironment facilitating tumor progression. However, accumulating evidence points toward the capacity of TEXs to efficiently stimulate immune responses against tumors provided they are appropriately administered. After briefly describing the function of exosomes in cancer biology and their communication with immune cells, we summarize in this review in vitro and preclinical studies eliciting the potency of TEXs in inducing effective anti-tumor responses and recently modified strategies further improving TEX-vaccination efficacy. We interpret the available data as TEXs becoming a lead in cancer vaccination based on tumor antigen-selective high immunogenicity. |
format | Online Article Text |
id | pubmed-7466856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74668562020-09-14 Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy Naseri, Marzieh Bozorgmehr, Mahmood Zöller, Margot Ranaei Pirmardan, Ehsan Madjd, Zahra Oncoimmunology Review Identification of immunogenic tumor antigens that are efficiently processed and delivered by dendritic cells to prime the immune system and to induce an appropriate immune response is a research hotspot in the field of cancer vaccine development. High biosafety is an additional demand. Tumor-derived exosomes (TEXs) are nanosized lipid bilayer encapsulated vesicles that shuttle bioactive information to the tumor microenvironment facilitating tumor progression. However, accumulating evidence points toward the capacity of TEXs to efficiently stimulate immune responses against tumors provided they are appropriately administered. After briefly describing the function of exosomes in cancer biology and their communication with immune cells, we summarize in this review in vitro and preclinical studies eliciting the potency of TEXs in inducing effective anti-tumor responses and recently modified strategies further improving TEX-vaccination efficacy. We interpret the available data as TEXs becoming a lead in cancer vaccination based on tumor antigen-selective high immunogenicity. Taylor & Francis 2020-06-16 /pmc/articles/PMC7466856/ /pubmed/32934883 http://dx.doi.org/10.1080/2162402X.2020.1779991 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Naseri, Marzieh Bozorgmehr, Mahmood Zöller, Margot Ranaei Pirmardan, Ehsan Madjd, Zahra Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title | Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title_full | Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title_fullStr | Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title_full_unstemmed | Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title_short | Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
title_sort | tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466856/ https://www.ncbi.nlm.nih.gov/pubmed/32934883 http://dx.doi.org/10.1080/2162402X.2020.1779991 |
work_keys_str_mv | AT naserimarzieh tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy AT bozorgmehrmahmood tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy AT zollermargot tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy AT ranaeipirmardanehsan tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy AT madjdzahra tumorderivedexosomesthenextgenerationofpromisingcellfreevaccinesincancerimmunotherapy |